Weil Company Inc. Has $2.76 Million Stake in Illumina, Inc. (NASDAQ:ILMN)

Weil Company Inc. grew its position in Illumina, Inc. (NASDAQ:ILMN) by 10.2% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 21,144 shares of the life sciences company’s stock after purchasing an additional 1,952 shares during the quarter. Illumina comprises 0.9% of Weil Company Inc.’s portfolio, making the stock its 29th biggest holding. Weil Company Inc.’s holdings in Illumina were worth $2,757,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Catalytic Wealth RIA LLC bought a new stake in shares of Illumina during the 3rd quarter worth $212,000. Ashton Thomas Securities LLC lifted its holdings in shares of Illumina by 8.9% in the third quarter. Ashton Thomas Securities LLC now owns 2,797 shares of the life sciences company’s stock worth $365,000 after acquiring an additional 228 shares during the last quarter. Los Angeles Capital Management LLC boosted its stake in shares of Illumina by 1,062.8% in the 3rd quarter. Los Angeles Capital Management LLC now owns 93,917 shares of the life sciences company’s stock valued at $12,248,000 after purchasing an additional 85,840 shares in the last quarter. Crossmark Global Holdings Inc. boosted its stake in shares of Illumina by 19.0% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 10,693 shares of the life sciences company’s stock valued at $1,395,000 after purchasing an additional 1,709 shares in the last quarter. Finally, Atria Investments Inc grew its holdings in shares of Illumina by 1.9% during the 3rd quarter. Atria Investments Inc now owns 19,517 shares of the life sciences company’s stock valued at $2,545,000 after purchasing an additional 364 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of research analyst reports. Robert W. Baird raised their target price on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Leerink Partners raised their price objective on Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Royal Bank of Canada upped their target price on Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Barclays lifted their price target on Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Finally, JPMorgan Chase & Co. upped their price objective on Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Illumina has an average rating of “Moderate Buy” and a consensus target price of $163.71.

Illumina Trading Up 0.8 %

NASDAQ:ILMN opened at $152.30 on Monday. Illumina, Inc. has a 52 week low of $92.26 and a 52 week high of $156.66. The firm has a 50-day moving average price of $138.09 and a two-hundred day moving average price of $123.55. The firm has a market cap of $24.15 billion, a price-to-earnings ratio of -15.17 and a beta of 1.13. The company has a debt-to-equity ratio of 0.94, a quick ratio of 0.86 and a current ratio of 2.43.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.26. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business’s revenue was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.33 earnings per share. On average, equities analysts expect that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.